Effect of Cremophor EL on the pharmacokinetics, antitumor activity and toxicity of doxorubicin in mice

Anti-Cancer Drugs

Volumn 9, Issue 9, 1998, Pages 809-815

  Badary, Osama A ^a   Al Shabanah, Othman A ^b   Al Gharably, Naji M ^b   Elmazar, Mohamed M A ^b  

^a African Union Organization St Abbassia   (Egypt)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Carcinoma; Cardiotoxicity; Cremophor EL; Cytotoxicity; Doxorubicin; Pharmacokinetics

Indexed keywords

ANTINEOPLASTIC AGENT; CREATINE KINASE; CREATINE KINASE MB; CREMOPHOR; DOXORUBICIN; GLYCOPROTEIN P; LACTATE DEHYDROGENASE; MALONALDEHYDE; SOLUBILIZER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CARCINOMA CELL; CARDIOTOXICITY; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CYTOTOXICITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG LIVER LEVEL; EHRLICH ASCITES TUMOR; FEMALE; HEART; INTRAPERITONEAL DRUG ADMINISTRATION; KIDNEY; LACTATE DEHYDROGENASE BLOOD LEVEL; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, EHRLICH TUMOR; DOXORUBICIN; DRUG SYNERGISM; FEMALE; GLYCEROL; HEART DISEASES; MICE; SURFACE-ACTIVE AGENTS; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED;

EID: 0031732373     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199810000-00011     Document Type: Article

References (33)

1. Carter SK. Adriamycin - a review. J Natl Cancer Inst 1975; 55: 1265-74.
2. Haanen C, Hillen G. Combination chemotherapy with Doxorubicin in 'bad risk' leukemia patients In: Haanen C. Hillen G, eds. Adriamycin review. Ghent: Eur Press Medicon 1975: 193-9.
3. Powis G, Hacker MP. The toxicity of anticancer drugs. New York: Pergamon Press 1996.
4. Chervinsky DS, Brecher ML, Baker RM, Hoelcle MJ, Tebbi CK. Reversal of C1300 murine neuroblastoma multidrug resistance by cremophor EL, a solvent for cyclosporin A. Cancer Biother 1993; 8: 67-75.
5. Fjallskog ML, Fril L, Bergh J. Paclitaxel induced cytotoxicity - the effects of Cremophor EL (Castor oil) on two human breast cancer cell lines with acquired multidrug resistant phenotype and induced expression of the permeability glycoprotein. Eur J Cancer 1994; 30: 687-90.
6. Fujimoto S. Study for modifying activity of solvents on antitumor activity of paclitaxel. Gan To Kagaku Ryoho 1994; 21: 665-70.
7. Nygren P, Csoka K, Jonsson B, et al. The cytotoxic activity of Taxol in primary cultures of tumor cells from patients is partly mediated by cremophor EL. Br J Cancer 1995; 71: 478-81.
8. Webster LK, Cosson EJ, Stokes KH, Millward MJ. Effect of the paclitaxel vehicle, cremophor EL, on the pharmacokinetics of Doxorubicin and Doxorubicinol in mice. Br J Cancer 1996; 73: 522-4.
9. Fojo AT, Uecla K, Slamon DJ, Poplack DG, Gottesman MM, Pastan I. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 1987; 84: 265-9.
10. Pastan I, Gottesman M. Multiple-drug resistance in human cancer. N Eng J Med 1987; 316: 1388-93.
11. Croop JM, Raymond M, Haber D, et al. The three mouse multidrug resistance (MDR) genes are expressed in a tissue-specific manner in normal mouse tissues. Mol Cell Biol 1989; 9: 1346-50.
12. Geran RI, Greenberg NH, MacDonald M, Schumacher AM, Abbott BJ. Protocols for screening chemical agents and natural products against animal tumors and other biological systems. Cancer Chemother Rep 1972; 3: 1-103.
13. Formelli F, Pollini C, Casazza AM, diMarco A, Mariani A. Fluorescence assays and pharmacokinetic studies of 4′-deoxydoxorubicin and Doxorubicin in organs of mice bearing solid tumors. Cancer Cbemotber Pharmacol 1981; 5: 139-44.
14. Rahman A, Ganjei A, Neefe JR. Comparative immunotoxicity of free Doxorubicin and Doxorubicin encapsulated in cardiolipin liposomes. Cancer Cbemotber Pharmacol 1986; 16: 28-34.
15. Benjamin RS, Riggs CE, Bachur NR. Plasma pharmacokinetics of adriamycin and its metabolites in patients with normal hepatic and renal function. Cancer Res 1977; 37: 1416-20.
16. Weisenthal L, Dill P, Kunick N, Lippman M. Comparison of dye exclusion assays with a cologenic assay in the determination of drug-induced cytotoxicity. Cancer Res 1983; 43: 258-84.
17. Buhl SN, Jackson KY. Optimal conditions and comparisons of lactate dehydrogenase catalysis of the lactate to pyruvate and pyruvate to lactate reactions in human serum at 25, 30 and 37 C. Clin Chem 1978; 24: 828-31.
18. Swanson JR, Wilkinson JH. Measurement of creatine kinase in serum. In: Cooper GR, ed. Standard methods of clinical chemistty. New York: Academic Press 1972; 7: 33-42.
19. Kachmar JF, Moss DW, Enzymes. In: Teitz W, ed. Fundamentals of clinical chemistry. Philadelphia: WB Saunders 1982: 565-95.
20. Sedlac J. Determination of total -SH groups. Anal Biochem 1968; 25: 192-5.
21. Uchiyama M, Mihara M. Determination of malonaldehyde precursor in tissues by thiobrabituric acid test. Anal Biochem 1978; 86: 271-8.
22. Litchfield JT, Wilcoxon F. A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther 1949; 257: 20-31.
23. Endicott JA, Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance Annu Rev Biochem 1989; 58: 137-71.
24. Ford JM, Hait WN. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 1990; 42: 155-99.
25. Borst P, Schinkel AH, Smit JM, et al. Classical and novel forms of multidrug resistance and the physiological functions of P-glycoproteins in mammals. Pharmacol Ther 1993; 60: 289-99.
26. Speeg VK, Maldonado AL. Effect of the non-immunosuppressive cyclosporin analog SDZ PSC-833 on colchicine and Doxorubicin biliary secretion by the rat in vivo. Cancer Chemother Pharmacol 1994; 34: 133-6.
27. Maniez-Devos DM, Baurain R, Trouet A, Lesne M. Doxorubicin pharmacokinetics in the rabbit. J Pharmacol 1985; 16: 159-69.
28. Kong Shang M, Cheng LS, Moan J, Rimington C. Interaction of Cremophor EL with human plasma. Int J Biochem 1991; 23: 473-8.
29. Sykes E, Woodburn K, Decker D, Kessel D. Effect of cremophor EL on distribution of Taxol to serum lipoproteins. Br J Cancer 1994; 70: 401-4.
30. Woodcock DM, Linsenmeyer ME, Chojnowski G, et al. Reversal of multidrug resistance by surfactants. Br J Cancer 1992; 66: 62-8.
31. Doroshow JH. Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Cancer Res 1983; 43: 460-572.
32. Gupta M, Singal PK. Time course of structure, function and metabolic changes due to an exogenous source of oxygen metabolites in rat heart. Can J Physiol Pharmacol 1989; 67: 1549-59.
33. Oison RD, MacDonald JS, Von Boxtel CJ, et al. Regulatory role of glutathione and soluble sulfhydryl groups in the toxicity of adriamycin. J Pharmacol Exp Ther 1980; 215: 450-4.